Back to search results

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China

    Contact: Study coordinator (Hongjing Jiang, MD,PhD) · jianghongjing@tmu.edu.cn · 18622221069
    Contact: Study coordinator (Xiaobin Shang, MD,PhD) · shangxiaobin@tmu.edu.cn · 18622221071
    Contact: Principal Investigator (Hongjing Jiang, MD,PhD)
    Contact: Principal Investigator (Yin Li, MD,PhD)
    Zhigang Li, MD,PhD (Sub-investigator)
    Hecheng Li, MD,PhD (Sub-investigator)
    Peng Zhang, MD,PhD (Sub-investigator)
    Ziqiang Tian, MD,PhD (Sub-investigator)
    Jianqun Ma, MD,PhD (Sub-investigator)
    Yegang MA, MD,PhD (Sub-investigator)
    Shiping Guo, MD,PhD (Sub-investigator)
    Haibo Cai, MD (Sub-investigator)
    Hengxiao Lu, MD (Sub-investigator)
    Lin Zhang, MD,PhD (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)